The Technical Analyst
MDxHealth SA [MDXH]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
MDxHealth SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.26% $2.45
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 66.86 mill |
| EPS: | -2.10 |
| P/E: | -1.170 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 27.29 mill |
| Avg Daily Volume: | 0.0755 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.170 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -1.170 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.14 - 2.65 ( +/- 10.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-03 | Mvm Partners, Llc | Buy | 1 000 000 | Common Stock |
| 2021-11-04 | Mvm Partners Llp | Buy | 0 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 1 transactions |
| Buy: 1 000 000 | Sell: 0 |
Forecast:
16:00 - $2.41
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.41
Forecast 2: 16:00 - $2.41
Forecast 3: 16:00 - $2.41
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.45 (4.26% ) |
| Volume | 0.0337 mill |
| Avg. Vol. | 0.0755 mill |
| % of Avg. Vol | 44.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MDXH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest Press Releases
2024-03-12 16:00:00 - Press Release
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test To Prostate Cancer Offering
Mdxhealth adds hereditary prostate cancer genetic test to prostate cancer offering irvine, ca, and herstal, belgium – march 12, 2024 (globenewswire) – mdxhealth sa (nasdaq: mdxh) (the “company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. with a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.
2024-03-06 16:00:00 - Press Release
Mdxhealth Announces Fourth Quarter And Full-year 2023 Financial Results
Mdxhealth announces fourth quarter and full-year 2023 financial results 2023 revenue grew by 89% to $70.2 million; excluding gps, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year conference call with q&a today at 4:30 pm est / 22:30 cet irvine, ca, and herstal, belgium – march 6, 2024 (globenewswire) – mdxhealth sa (nasdaq: mdxh) (the "company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended december 31, 2023. michael k.
2024-02-21 17:00:00 - Press Release
Mdxhealth To Present Fourth Quarter And Full Year 2023 Financial Results And Corporate Update On March 6
Mdxhealth to present fourth quarter and full year 2023 financial results and corporate update on march 6
2024-02-16 08:45:00 - Press Release
Mdxhealth Announces Resignation Of Board Member
Mdxhealth announces resignation of board member irvine, ca, and herstal, belgium – february 16, 2024 (globenewswire) – mdxhealth sa (nasdaq: mdxh) (the "company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that jan pensaert has stepped down from the board of directors of mdxhealth. his resignation was effective as of february 15, 2024.
2024-01-08 16:00:00 - Press Release
Mdxhealth Reports Preliminary Fourth Quarter And Full Year 2023 Revenues And Issues 2024 Revenue Guidance
Mdxhealth reports preliminary fourth quarter and full year 2023 revenues and issues 2024 revenue guidance irvine, ca, and herstal, belgium – january 8, 2024 (globenewswire) – mdxhealth sa (nasdaq: mdxh), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter and full year 2023 revenues and issued 2024 revenue guidance. the company expects to report fourth quarter and full year 2023 revenues of approximately $19.4 and $70.2 million, respectively, with a year-end cash balance of $22.4 million, which reflects $2.3 million of non-operating and non-recurring cash use in the fourth quarter, primarily attributed to the transition to a sole listing on nasdaq.
Latest News
2024-03-06 21:07:06 - Seeking Alpha
MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Mark Massaro - BTIG Operator Good afternoon, ladies and gentlemen and welcome to the MDxHealth Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.
2024-02-21 17:00:00 - GlobeNewsWire
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
2023-11-11 17:33:09 - Seeking Alpha
MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Daniel Sammarco - TD Cowen Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Operator Good afternoon, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2023 Earnings Call. Before we begin, I would like to remind everyone that we will make forward-looking statements during today's call, whether in prepared remarks or during the Q&A session.
2023-10-19 11:18:59 - Zacks Investment Research
MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?
MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-08-23 20:41:05 - Seeking Alpha
MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q2 2023 Earnings Call Transcript August 23, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William Blair Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Francois Brisebois - Oppenheimer & Co Operator Greetings, and welcome to MDxHealth's 2023 Q2 and Midyear Earnings Call. [Operator Instructions].
2023-08-23 18:47:22 - Zacks Investment Research
MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates
MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.70 per share a year ago.
2023-08-10 16:00:00 - GlobeNewsWire
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23
2023-05-23 16:00:00 - GlobeNewsWire
MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference
NEWS RELEASE May 23 , 2023, 4 PM ET/ 22: 0 0 CET MDxHealth to Present at the 43 rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present at William Blair's 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET. A live webcast of the presentation will be available on the Company's website.
2023-05-15 21:24:11 - Seeking Alpha
MDxHealth SA (MXDHF) Q1 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Mark Massaro - BTIG Operator Greetings. Welcome to the MDxHealth First Quarter 2023 Earnings Call.
2023-05-15 18:59:21 - Zacks Investment Research
MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.05 per share a year ago.